




# MEDICINAL PRODUCTS 2021

IMMUCELL CORP DE  
Rank 14 of 52

ImmuCell





The relative strengths and weaknesses of IMMUCCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 54% points. The greatest weakness of IMMUCCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 88%, being 143% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	12,157
Assets, Non-Current	1,247
General and Administrative Expense	12,368
Goodwill	191
Liabilities, Current	2,211
Liabilities, Non-Current	9,872
Other Assets	0
Other Compr. Net Income	44
Other Expenses	-10
Other Liabilities	0
Other Net Income	348
Other Revenues	15,342
Property, Plant and Equipment, Net	26,755
Research and Development	4,355

Output Variable	Value in 1000 USD
Liabilities	12,083
Assets	40,350
Expenses	16,712
Revenues	15,342
Stockholders Equity	28,266
Net Income	-1,022
Comprehensive Net Income	-1,000
Economic Capital Ratio	88%